Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID), and isoniazid, an antibiotic primarily used to treat tuberculosis. Ketoprofen acts by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever. Isoniazid works as a prodrug activated by the mycobacterial enzyme KatG; it generates reactive oxygen species that disrupt the mycobacterial cell wall, making it bactericidal against replicating Mycobacterium tuberculosis. The combination of these two drugs does not have a unique clinical indication or established use together but may be considered in rare cases where both anti-inflammatory and antimycobacterial effects are needed. Coadministration should be approached with caution due to potential additive hepatotoxicity[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketoprofen + isoniazid.